1666 related articles for article (PubMed ID: 32198236)
1. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.
Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ
Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236
[TBL] [Abstract][Full Text] [Related]
2. The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review).
Wang SW; Sun YM
Int J Oncol; 2014 Apr; 44(4):1032-40. PubMed ID: 24430672
[TBL] [Abstract][Full Text] [Related]
3. 17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells.
Wang Y; Ma X; Yan S; Shen S; Zhu H; Gu Y; Wang H; Qin G; Yu Q
Cancer Res; 2009 Sep; 69(18):7302-10. PubMed ID: 19706767
[TBL] [Abstract][Full Text] [Related]
4. Zelnorm, an agonist of 5-Hydroxytryptamine 4-receptor, acts as a potential antitumor drug by targeting JAK/STAT3 signaling.
Zhang L; Song Q; Zhang X; Li L; Xu X; Xu X; Li X; Wang Z; Lin Y; Li X; Li M; Su F; Wang X; Qiu P; Guan H; Tang Y; Xu W; Yang J; Zhao C
Invest New Drugs; 2020 Apr; 38(2):311-320. PubMed ID: 31087223
[TBL] [Abstract][Full Text] [Related]
5. Involvement of the janus kinase/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis.
Benveniste EN; Liu Y; McFarland BC; Qin H
J Interferon Cytokine Res; 2014 Aug; 34(8):577-88. PubMed ID: 25084174
[TBL] [Abstract][Full Text] [Related]
6. Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells.
Chen X; Du Y; Nan J; Zhang X; Qin X; Wang Y; Hou J; Wang Q; Yang J
PLoS One; 2013; 8(5):e63697. PubMed ID: 23704931
[TBL] [Abstract][Full Text] [Related]
7. MiR-21 inhibitor improves locomotor function recovery by inhibiting IL-6R/JAK-STAT pathway-mediated inflammation after spinal cord injury in model of rat.
Ning SL; Zhu H; Shao J; Liu YC; Lan J; Miao J
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):433-440. PubMed ID: 30720148
[TBL] [Abstract][Full Text] [Related]
8. Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms.
Montero P; Milara J; Roger I; Cortijo J
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207510
[TBL] [Abstract][Full Text] [Related]
9. Suppressor of cytokine signaling 1-derived peptide inhibits Janus kinase/signal transducers and activators of transcription pathway and improves inflammation and atherosclerosis in diabetic mice.
Recio C; Oguiza A; Lazaro I; Mallavia B; Egido J; Gomez-Guerrero C
Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):1953-60. PubMed ID: 25012131
[TBL] [Abstract][Full Text] [Related]
10. Evidence for a non-canonical JAK/STAT signaling pathway in the synthesis of the brain's major ion channels and neurotransmitter receptors.
Hixson KM; Cogswell M; Brooks-Kayal AR; Russek SJ
BMC Genomics; 2019 Aug; 20(1):677. PubMed ID: 31455240
[TBL] [Abstract][Full Text] [Related]
11. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.
Bonetto A; Aydogdu T; Jin X; Zhang Z; Zhan R; Puzis L; Koniaris LG; Zimmers TA
Am J Physiol Endocrinol Metab; 2012 Aug; 303(3):E410-21. PubMed ID: 22669242
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells.
Nam S; Wen W; Schroeder A; Herrmann A; Yu H; Cheng X; Merz KH; Eisenbrand G; Li H; Yuan YC; Jove R
Mol Oncol; 2013 Jun; 7(3):369-78. PubMed ID: 23206899
[TBL] [Abstract][Full Text] [Related]
13. Parthenolide Inhibits STAT3 Signaling by Covalently Targeting Janus Kinases.
Liu M; Xiao C; Sun M; Tan M; Hu L; Yu Q
Molecules; 2018 Jun; 23(6):. PubMed ID: 29921758
[TBL] [Abstract][Full Text] [Related]
14. Porcine Reproductive and Respiratory Syndrome Virus Antagonizes JAK/STAT3 Signaling via nsp5, Which Induces STAT3 Degradation.
Yang L; Wang R; Ma Z; Xiao Y; Nan Y; Wang Y; Lin S; Zhang YJ
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881658
[TBL] [Abstract][Full Text] [Related]
15. Revisiting STAT3 signalling in cancer: new and unexpected biological functions.
Yu H; Lee H; Herrmann A; Buettner R; Jove R
Nat Rev Cancer; 2014 Nov; 14(11):736-46. PubMed ID: 25342631
[TBL] [Abstract][Full Text] [Related]
16. Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.
Burger R; Le Gouill S; Tai YT; Shringarpure R; Tassone P; Neri P; Podar K; Catley L; Hideshima T; Chauhan D; Caulder E; Neilan CL; Vaddi K; Li J; Gramatzki M; Fridman JS; Anderson KC
Mol Cancer Ther; 2009 Jan; 8(1):26-35. PubMed ID: 19139110
[TBL] [Abstract][Full Text] [Related]
17. Psoriasis: A STAT3-Centric View.
Calautti E; Avalle L; Poli V
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316631
[TBL] [Abstract][Full Text] [Related]
18. The JAK/STAT3 axis: A comprehensive drug target for solid malignancies.
Huynh J; Etemadi N; Hollande F; Ernst M; Buchert M
Semin Cancer Biol; 2017 Aug; 45():13-22. PubMed ID: 28647610
[TBL] [Abstract][Full Text] [Related]
19. Targeting STAT3 signaling in kidney disease.
Pace J; Paladugu P; Das B; He JC; Mallipattu SK
Am J Physiol Renal Physiol; 2019 Jun; 316(6):F1151-F1161. PubMed ID: 30943069
[TBL] [Abstract][Full Text] [Related]
20. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Lai SY; Johnson FM
Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
